Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07080931

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of 5% Minoxidil Foam in the Treatment of Female Androgenetic Alopecia

Led by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Updated on 2026-03-05

294

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness of a once-daily 5% minoxidil foam compared to a placebo in women with androgenetic alopecia. This study aims to measure hair growth improvements using the Target Area Terminal Hair Count (TAHC) as the main endpoint. It is a Phase 3, randomized, double-blind, placebo-controlled trial sponsored by Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. Participants will apply either 5% minoxidil foam or a placebo foam once daily, in the morning or evening, with a maximum dose of 1 gram per day for up to 24 weeks. The study involves two groups: one receiving the active foam and the other receiving placebo. Treatment adherence and effects will be monitored throughout the 24-week period. During the study, participants will undergo digital phototrichogram analysis at weeks 6, 12, 18, and 24 to measure changes in hair count. They will also self-assess their satisfaction at these times. Safety and efficacy will be evaluated through these measures, with the main outcome assessed at week 24. The total participation duration is approximately 24 weeks.

CONDITIONS

Brief Title

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntarily agree to participate and provide written informed consent
  • Female aged 18 years or older
  • Diagnosed by an investigator with androgenetic alopecia
  • Hair loss severity graded D3 to D6 on the Savin scale
  • Willing to keep the same hairstyle, hair color, and hair length at each visit
  • No pregnancy plans during the study and 3 months after last dose, with commitment to effective contraception
  • Negative serum pregnancy test within 7 days before first study treatment
Not Eligible

You will not qualify if you...

  • Known allergy to minoxidil or any ingredient in the study product
  • Hair loss disorders other than androgenetic alopecia
  • Scalp conditions interfering with effectiveness evaluation
  • Currently breastfeeding
  • History of low or uncontrolled high blood pressure
  • Significant abnormal lab results or ECG issues at screening
  • History of cancer before screening
  • Conditions that affect hair growth or study results
  • Prior use of systemic drugs affecting hair growth before screening
  • Previous use of topical minoxidil on affected areas
  • No response to earlier minoxidil treatment for hair loss
  • History of 5α-reductase inhibitor, spironolactone, or cyproterone use
  • Previous autologous platelet-rich plasma treatments
  • Past chemotherapy, scalp radiation, laser therapy, or scalp surgery for hair loss
  • Use of medical shampoos or solutions interfering with study
  • Plans for hair transplantation or use of hair weaving, non-breathable wigs, or hair bonding during study
  • Participation in other interventional trials within 3 months before screening or planned concurrent trials
  • Major surgery within 3 months before screening or planned during study
  • Other conditions judged by the investigator to affect compliance or suitability

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 24 weeks

Participants apply 5% minoxidil foam or placebo topically once daily for up to 24 weeks.

Visits at Weeks 6, 12, 18, and 24 for assessments

Trial Site Locations

Total: 1 location

1

Beijing, China

Beijing, China

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Pilot Study Evaluating the Safety and Efficacy of a 1470nm...

Scarring Alopecia

Actively Recruiting

1 location

National, Multicentre, Randomized, Double-blind, Double-dumm...

Androgenetic Alopecia

Actively Recruiting

1 location

International Phase III, Multi Center, Randomized, Double Bl...

Androgenetic Alopecia

Actively Recruiting

13 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here